Clinical Trial Update: A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study evaluating subcutaneous epoetin in chronic renal failure patients on hemodialysis receiving maintenance epoetin; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Failure Requiring Hemodialysis

Drugs mentioned

• epoetin (epoetin)

Snippet

Sponsor: Pfizer | Conditions: Chronic Renal Failure Requiring Hemodialysis | Phase 3 | Status: COMPLETED | Results posted: 2018-07-19